Acelyrin Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Acelyrin, Inc Expected to Post Q2 2024 Earnings of ($0 33) Per Share (NASDAQ:SLRN)

Acelyrin, Inc. (NASDAQ:SLRN – Free Report) – Equities researchers at HC Wainwright boosted their Q2 2024 EPS estimates for shares of Acelyrin in a report released on Wednesday, May 22nd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.33) for the quarter, up from their previous estimate […]

New yorkUnited statesHidradenitis suppurativaZurcher kantonalbank zurich cantonalbankAcelyrin incYork state common retirement fundAmeritas investment partners incChina universal asset management coWells fargo companyFree reportWells fargoGet free reportInvestment partnersKantonalbank zurich cantonalbankChina universal asset managementPsoriatic arthritis

Acelyrin (NASDAQ:SLRN) Given Buy Rating at HC Wainwright

Acelyrin (NASDAQ:SLRN) Given Buy Rating at HC Wainwright
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Hidradenitis suppurativaShao lee linVanguard group incWells fargo companyAcelyrin incAcelyrin company profileDecheng capitalFree reportWells fargoModerate buyGet free reportLee linCapital managementStempoint capitalPoint capitalPsoriatic arthritis

Acelyrin, Inc (NASDAQ:SLRN) Receives $23 67 Average PT from Analysts

Acelyrin, Inc (NASDAQ:SLRN) Receives $23 67 Average PT from Analysts
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Shao lee linHidradenitis suppurativaDecheng capitalWells fargo companyAcelyrin company profileSecurities exchange commissionVanguard group incAcelyrin incWalleye capitalGet free reportLee linExchange commissionCapital managementGet freePsoriatic arthritisAcelyrin daily

Acelyrin, Inc (NASDAQ:SLRN) Given Consensus Rating of Moderate Buy by Analysts

Acelyrin, Inc (NASDAQ:SLRN) Given Consensus Rating of Moderate Buy by Analysts
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesHidradenitis suppurativaShao lee linAcelyrin incWells fargo companyAmeritas investment partners incSecurities exchange commissionAcelyrin company profileYork state common retirement fundChina universal asset management coGet free reportMarketbeat ratingsLee linExchange commissionInvestment partners

HC Wainwright Cuts Acelyrin (NASDAQ:SLRN) Price Target to $18 00

HC Wainwright Cuts Acelyrin (NASDAQ:SLRN) Price Target to $18 00
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesHidradenitis suppurativaShao lee linZurcher kantonalbank zurich cantonalbankAcelyrin incYork state common retirement fundAcelyrin company profileWells fargo companyChina universal asset management coFree reportWells fargoModerate buyGet free reportLee linKantonalbank zurich cantonalbank